115.25
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead and Arcus Advance Cancer Treatment Study with AB308 and Zimberelimab - TipRanks
Are Wall Street Analysts Bullish On Gilead Sciences Stock? - Barchart.com
Gilead files covid 19 remdesivir actions against Chinese military research institute - IAM Patent
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - Yahoo Finance
[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
NY Judge Faces Recusal Request Over Gilead Stock Holdings - Law360
Gilead Sciences’ TAF Study in Children with Hepatitis B: An Update - TipRanks
AbbVie, Gilead and GSK back World Hepatitis Day, seeking to tackle stigma to drive elimination - Fierce Pharma
Gilead Sciences’ Strategic Positioning and Growth Prospects in the HIV Prevention Market Justify Buy Rating - TipRanks
Gilead price collects profitsForecast today29-07-2025 - Economies.com
Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com
Order Flow Trends Show Accumulation in Gilead Sciences Inc.Long Hold Safe Return Strategy Reviewed - metal.it
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Why Gilead Sciences Stock Slipped Today - Yahoo Finance
Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha
Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits
Is Gilead Sciences Inc. stock overvalued or undervaluedConsistent double returns - jammulinksnews.com
Gilead Sciences Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily
TD Cowen Remains Bullish on Gilead Sciences (GILD) - Insider Monkey
Citi Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey
What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st
Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval - The Hindu
Gilead Sciences Stock Surges Amid Promising Trials - TipRanks
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live
Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance
Why Gilead Sciences Stock Just Popped - MSN
Gilead Sciences (GILD) Receives Upgraded Rating from Needham | G - GuruFocus
Gilead Sciences’ Latest Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com
EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus
Gilead stock upgraded at Needham on new HIV drug (GILD:NASDAQ) - Seeking Alpha
What analysts say about Gilead Sciences Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener
This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits
Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha
Gilead Sciences’ Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued Potential - TipRanks
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention - BioSpace
Gilead receives positive EU opinion for twice-yearly HIV prevention drug - StreetInsider
Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention - Investing.com
Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention By Investing.com - Investing.com Nigeria
Gilead Sciences and the Breakthrough Approval of Lenacapavir for HIV PrEP: A New Era in Global Health and Market Leadership - AInvest
Gilead Receives Positive Chmp Opinions Under Accelerated Review From European Medicines Agency For Twice-Yearly Lenacapavir For HIV Prevention - vih.org
Is Gilead Sciences Inc. a good long term investmentMarket-leading profit generation - PrintWeekIndia
What drives Gilead Sciences Inc. stock priceAccelerated wealth expansion - PrintWeekIndia
Why Gilead Sciences Inc. stock attracts strong analyst attentionSmall Risk Large Return Trades - beatles.ru
Is Gilead Sciences Inc. stock a growth or value playTremendous gains - jammulinksnews.com
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - BioSpace
Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications - TipRanks
Gilead Sciences Advances HIV Prevention with New Clinical Study - TipRanks
Looking Back to the Future: Gilead’s Long-Standing Commitment To Help End the HIV Epidemic - CSRwire
Attorney General Jeff Jackson Secures Over $200 Million from Gilead Sciences for Paying Kickbacks to Doctors - NCDOJ (.gov)
AG Jackson announces major settlement with Gilead Sciences over kickbacks - WPDE
Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know - TradingView
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):